SL Science Holding Ltd

Das jüngste Quartal, das uns für SL Science Holding Ltd vorliegt

Aus dem eigenen 6-K des Unternehmens.

Was das Management sagte

“The first half of 2026 marked a period of profound structural execution and milestone achievement for SL Science. We successfully closed our business combination on June 12, and listed on the Nasdaq Global Market on June 15, supported by a concurrent $7.8 million PIPE financing. This capitalization provides the foundational strength required to advance our clinical programs. Concurrently, our deliberate pivot from direct retail to a B2B wholesale distribution model in Taiwan yielded immediate results. We drove a 23% increase in top-line revenue and expanded our gross margin to over 40% through enhanced volume predictability and optimized supplier pricing agreements,”

Wörtlich aus der Veröffentlichung zitiert und nur gezeigt, wenn die Einreichung es einer namentlich genannten Person zuordnet.

Was SL Science Holding Ltd macht

SL Science Holding Limited is a biomedical company specializing in developing innovative cellular and gene therapies. Established with a commitment to advancing regenerative medicine and cancer treatment, the Company hopes to utilize immune cell technologies to target cancer, thus potentially offering expansive medical applications for its products. With technologies such as Gamma Delta T cells targeting solid tumor indications including pancreatic and brain cancers, SL Science aims to create cellular therapies that the Company believes have the potential to advance the cell therapy and immuno-oncology sector within the broader biopharmaceutical industry.

Die Selbstbeschreibung des Unternehmens, wie sie am Fuß der Veröffentlichung steht.